<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03884452</url>
  </required_header>
  <id_info>
    <org_study_id>P01030</org_study_id>
    <secondary_id>P01030</secondary_id>
    <secondary_id>MK-0653-018</secondary_id>
    <nct_id>NCT03884452</nct_id>
  </id_info>
  <brief_title>Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)</brief_title>
  <official_title>A Phase III Efficacy And Safety Study of Ezetimibe (SCH58235) 10 mg in Addition to Atorvastatin or Simvastatin in the Therapy of Homozygous Familial Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy and the safety of ezetimibe
      (SCH 58235) co-administered with either atorvastatin or simvastatin in participants with
      homozygous familial hypercholesterolemia (FH).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 3, 2000</start_date>
  <completion_date type="Actual">May 24, 2001</completion_date>
  <primary_completion_date type="Actual">May 24, 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in Low Density Lipoprotein Cholesterol (LDL-C) measured directly</measure>
    <time_frame>Baseline and Up to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with an Adverse Event (AE)</measure>
    <time_frame>Up to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in calculated LDL-C</measure>
    <time_frame>Baseline and Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Total Cholesterol (TC)</measure>
    <time_frame>Baseline and Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Triglycerides (TG)</measure>
    <time_frame>Baseline and Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in High-density-lipoprotein cholesterol (HDL-C)</measure>
    <time_frame>Baseline and Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in High-density-lipoprotein 2 cholesterol (HDL2-C)</measure>
    <time_frame>Baseline and Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in High-density-lipoprotein 3 cholesterol (HDL3-C)</measure>
    <time_frame>Baseline and Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Apolipoprotein A-I (Apo A-I)</measure>
    <time_frame>Baseline and Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Apolipoprotein B (Apo B)</measure>
    <time_frame>Baseline and Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Lipoprotein(a) [Lp(a)]</measure>
    <time_frame>Baseline and Up to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Atorvastatin 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg atorvastatin taken orally, once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe + Atorvastatin 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg ezetimibe and 40 mg atorvastatin taken orally, once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe + Atorvastatin 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg ezetimibe and 80 mg atorvastatin taken orally, once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg simvastatin taken orally, once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe + Simvastatin 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg ezetimibe and 40 mg simvastatin taken orally, once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe + Simvastatin 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg ezetimibe and 80 mg simvastatin taken orally, once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Tablets taken orally once daily in the morning</description>
    <arm_group_label>Atorvastatin 80 mg</arm_group_label>
    <arm_group_label>Ezetimibe + Atorvastatin 40 mg</arm_group_label>
    <arm_group_label>Ezetimibe + Atorvastatin 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Tablets taken orally once daily in the morning or evening</description>
    <arm_group_label>Ezetimibe + Simvastatin 40 mg</arm_group_label>
    <arm_group_label>Ezetimibe + Simvastatin 80 mg</arm_group_label>
    <arm_group_label>Simvastatin 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Tablet taken orally once daily in the morning or evening</description>
    <arm_group_label>Ezetimibe + Atorvastatin 40 mg</arm_group_label>
    <arm_group_label>Ezetimibe + Atorvastatin 80 mg</arm_group_label>
    <arm_group_label>Ezetimibe + Simvastatin 40 mg</arm_group_label>
    <arm_group_label>Ezetimibe + Simvastatin 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Ezetimibe</intervention_name>
    <description>Tablets taken orally once daily in the morning or evening</description>
    <arm_group_label>Atorvastatin 80 mg</arm_group_label>
    <arm_group_label>Simvastatin 80 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  With a diagnosis of homozygous familial hypercholesterolemia

          -  All females must have a negative pregnancy test prior to study entry. Women of child
             bearing potential must agree to practice an effective barrier method of birth control
             for the duration of the study, until one month after treatment.

          -  Postmenopausal women who are receiving postmenopausal hormonal therapy or raloxifene
             must be maintained on a stable estrogen (ERT), estrogen/progestin (HRT) or raloxifene
             regimen during the study period. ERT, HRT or raloxifene cannot be changed during study
             period.

          -  Must follow prescribed or stricter diet, and demonstrate completion of Diet Diaries

        Exclusion Criteria:

          -  A history of mental instability, drug or alcohol abuse; or have been treated or are
             being treated for severe psychiatric illness which, in the opinion of the
             Investigator, may interfere with optimal participation in the study.

          -  With underlying disease likely to limit life span to less than 1 year.

          -  Have previously been randomized in any studies examining ezetimibe

          -  Pregnant or lactating women.

          -  With known hypersensitivity or any contraindication to statin therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <results_reference>
    <citation>Gagn√© C, Gaudet D, Bruckert E; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002 May 28;105(21):2469-75.</citation>
    <PMID>12034651</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>June 11, 2019</last_update_submitted>
  <last_update_submitted_qc>June 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

